Krystal Biotech, Inc.
KRYS
$143.96
-$2.34-1.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.50% | 116.86% | 715.58% | 275.67% | 175.45% |
| Total Depreciation and Amortization | -50.02% | -25.95% | -33.19% | -18.81% | -9.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 180.65% | 175.51% | 168.92% | 163.56% | -276.51% |
| Change in Net Operating Assets | 91.19% | 4.23% | 62.47% | -169.34% | -1,807.94% |
| Cash from Operations | 1,267.39% | 396.20% | 238.98% | 160.97% | 83.65% |
| Capital Expenditure | -65.39% | -19.59% | 64.08% | 65.17% | 78.07% |
| Sale of Property, Plant, and Equipment | -99.57% | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -292.67% | -366.63% | -2,761.78% | -3,164.04% | -803.53% |
| Cash from Investing | -469.02% | -462.05% | -297.78% | -202.55% | 253.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.76% | -91.76% | -84.08% | -84.02% | -77.88% |
| Repurchase of Common Stock | -158.60% | -158.60% | -619.09% | -619.09% | -619.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -113.10% | -98.13% | -86.68% | -86.61% | -80.60% |
| Foreign Exchange rate Adjustments | 431.65% | -807.46% | -193.59% | 92.98% | -302.90% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.50% | -123.02% | -106.85% | -99.61% | 22.32% |